54475-92-2

Usage

InChI:InChI=1/C9H9ClN2/c10-8-3-1-4-9(7-8)12-6-2-5-11/h1,3-4,7,12H,2,6H2

Upstream product

• 141-85-5 3-chloroaniline hydrochloride 
• 107-13-1 acrylonitrile 
• 108-42-9 3-chloro-aniline 

Downstream Products

• 1093868-87-1 tert-butyl 2-((3-chlorophenyl)(2-cyanoethyl)amino)-2-oxoethyl(methyl)carbamate 
• 102450-77-1 N₁-(3-chlorophenyl)propane-1,3-diamine 
• 1093868-84-8 methyl 3-(3-chlorophenylamino)propylcarbamate 
• 1093868-90-6 methyl 3-((3-chlorophenyl)(2-(methylamino)ethyl)amino)propylcarbamate 
• 1093868-86-0 methyl 3-(N-(3-chlorophenyl)-2-(methylamino)acetamido)propylcarbamate 
• 1093868-88-2 tert-butyl 2-((3-aminopropyl)(3-chlorophenyl)amino)ethyl(methyl)carbamate 
• 1093868-89-3 tert-butyl 2-((3-(methoxycarbonylamino)propyl)(3-chlorophenyl)amino)ethyl(methyl)carbamate 
• 1093868-85-9 tert-butyl 2-((3-chlorophenyl)(3-(methoxycarbonylamino)propyl)amino)-2-oxoethyl(methyl)carbamate 

Relevant academic research and scientific papers

An effective aza-michael addition of aromatic amines to electron-deficient alkenes in alkaline Al2O3

Aza-Michael addition of aromatic or aliphatic amines with various electron-deficient alkenes was performed using alkaline Al2O 3 as solid media at room temperature afforded the corresponding Michael addition products in good to excellent yields.The alkaline Al 2O3 can be easily recovered and reused.

RENIN INHIBITORS

The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagon